124. 皮質下梗塞と白質脳症を伴う常染色体優性脳動脈症 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Clinical trials / Disease details
臨床試験数 : 12 / 薬物数 : 14 - (DrugBank : 5) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 11
Showing 1 to 7 of 7 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2004-001162-40-IT (EUCTR) | 05/04/2005 | 21/09/2005 | An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment. An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The ... | An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment. An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The ... | Donezepil HCl for treatment of patients with CADASIL (Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy) who have cognitive impairment. MedDRA version: 6.1;Level: PT;Classification code 10009843 Donezepil HCl for treatment of patients with CADASIL (Cerebral autosomal dominant arteriopathy with ... | Trade Name: ARICEPT 5*28 CPR 5 MG Product Name: NA Product Code: NA INN or Proposed INN: Donepezil | EISAI LTD UK | NULL | Not Recruiting | Female: yes Male: yes | Finland;United Kingdom;Germany;Spain;Italy;Sweden | ||||
| 2 | EUCTR2004-001162-40-SE (EUCTR) | 01/04/2005 | 03/02/2005 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) ... | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezilhydrochlori ... | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Finland;United Kingdom;Germany;Spain;Italy;Sweden | |||
| 3 | EUCTR2004-001162-40-ES (EUCTR) | 29/03/2005 | 20/01/2006 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) ... | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezilhydrochlori ... | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): Therapeutic use (Phase 4): Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Pha ... | Finland;Spain;Germany;Italy;United Kingdom;Sweden | ||
| 4 | EUCTR2004-001162-40-FI (EUCTR) | 08/03/2005 | 28/12/2004 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) ... | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezilhydrochlori ... | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Finland;Spain;Germany;Italy;United Kingdom;Sweden | ||
| 5 | EUCTR2004-001162-40-GB (EUCTR) | 24/02/2005 | 23/02/2005 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy (CADASIL). CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy (CADASIL) ... | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezilhydrochlori ... | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): Therapeutic use (Phase 4): Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Pha ... | Finland;Spain;Germany;Italy;United Kingdom;Sweden | ||
| 6 | NCT00103948 (ClinicalTrials.gov) | February 2005 | 17/2/2005 | The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Co ... | An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The ... | Cognitive Impairment | Drug: Aricept | Eisai Limited | NULL | Completed | 25 Years | 70 Years | Both | 165 | Phase 2 | United States;Australia;Spain;Canada;Finland;France;Germany;Italy;Sweden;Switzerland;United Kingdom |
| 7 | EUCTR2004-001162-40-DE (EUCTR) | 25/01/2005 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the ... | Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy (CADASIL) ... | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezilhydrochlori ... | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Finland;Spain;Germany;Italy;United Kingdom;Sweden |